Key Players in the Vietnam Atherosclerosis Market | Market Insights 2026

Key Players in the Vietnam Atherosclerosis Market

The Vietnam Atherosclerosis Market is an essential segment of the country’s healthcare sector, featuring a mix of multinational pharmaceutical giants and prominent domestic distributors. These players compete for the larger market share by developing advanced lipid-lowering therapies, anti-platelet medications, and fixed-dose combinations tailored to the increasing occurrence of cardiovascular diseases. Key companies driving the market include Sanofi S.A., Pfizer Inc., AstraZeneca plc, and Novartis AG.

Vietnam Atherosclerosis Market Overview

According to 6Wresearch, The Vietnam atherosclerosis market is positioned for significant growth, spurred by the rising older population and an increase in cardiovascular conditions. Atherosclerosis, specified by the build-up of fats and cholesterol in the walls of artery, remains the major cause behind strokes and heart attacks in the country.

The market is highly influenced by government initiatives aimed at improving healthcare infrastructure and the expansion of middle class's demand for high-quality chronic disease management. There is a significant shift towards preventive cardiology and the adoption of sophisticated diagnostic tools. Along with this, a key trend shaping the future of this segment is the integration of digital health monitoring.

Competitive Landscape

The competitive landscape of the Vietnam atherosclerosis industry is determined by the dominance of global biopharmaceutical giants along with a growing network of local manufacturing and distribution channels. Leading companies maintain an effective market share through extensive clinical data, brand trust, and strategic partnerships with hospital networks and retail pharmacies. Moreover, these companies are investing heavily towards medical education and patient awareness programs.

Below is a list of leading players operating in the Vietnam Atherosclerosis Market:

1. Sanofi S.A.

A major player in Vietnam, Sanofi offers a strong portfolio of cardiovascular medicines, particularly lipid-lowering therapies for managing cholesterol and atherosclerosis.

2. Pfizer Inc.

Pfizer maintains a strong footprint in Vietnam through its widely recognized statin brands and innovative cardiovascular treatment solutions.

3. AstraZeneca plc

Focuses on cardiovascular, renal, and metabolic (CVRM) diseases, offering advanced therapies for atherosclerosis and related complications.

4. Novartis AG

A global leader in innovative therapies, including advanced cholesterol-lowering treatments such as siRNA-based solutions.

5. Bayer AG

Provides essential cardiovascular and antithrombotic medications widely used in preventing atherosclerosis-related complications.

6. Abbott Laboratories

A key supplier of cardiovascular drugs and medical devices such as stents for treating arterial blockages.

7. Merck & Co., Inc.

Engaged in supplying specialty medicines that target key risk factors associated with atherosclerosis and cardiovascular diseases.

8. GlaxoSmithKline plc

Supports chronic disease management with a range of essential cardiovascular medications in Vietnam.

9. Takeda Pharmaceutical Company Limited

Expanding its presence in Vietnam, Takeda offers specialized therapies for cardiovascular and metabolic disorders.

10. Aurophar Pharmaceuticals Co. Ltd

A prominent domestic player providing affordable, high-quality treatments for heart diseases and blood clotting disorders.

Key Players in the Vietnam Atherosclerosis Market 2026 : FAQs